Our results suggest that tracking blood concentration of CD45+ EV might be used to monitor therapy responses of pancreatic cancer patients, as blood levels of LEVs significantly decreased in patients who achieved disease control, but not in those with progressive disease. Here, PTPRC is linked to familial pancreatic carcinoma.